Literature DB >> 23878283

Triple-negative and non-triple-negative invasive breast cancer: association between MR and fluorine 18 fluorodeoxyglucose PET imaging.

Marjan S Bolouri1, Sjoerd G Elias, Dorota J Wisner, Spencer C Behr, Randall A Hawkins, Sachiko A Suzuki, Krysta S Banfield, Bonnie N Joe, Nola M Hylton.   

Abstract

PURPOSE: To assess the relationship between parameters measured on dynamic contrast material-enhanced (DCE) magnetic resonance (MR) imaging and fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in primary invasive breast cancer.
MATERIALS AND METHODS: This HIPAA-compliant study was a retrospective review of medical records and therefore approved by the institutional review board without the requirement for informed consent. Patients with a diagnosis of invasive breast cancer from January 2005 through December 2009 who underwent both DCE MR imaging and FDG PET/CT before treatment initiation were retrospectively identified. Fractional volumes were measured for ranges of signal enhancement ratio (SER) values from DCE MR imaging data and compared with maximum standardized uptake values (SUVmax) from FDG PET/CT data. Linear regression analysis was performed to clarify the relationship between SER and SUVmax, adjusting for tumor size, pathologic grade, and receptor status.
RESULTS: Analyzed were 117 invasive breast cancers in 117 patients. Overall, a higher percentage of high washout kinetics was positively associated with SUVmax (1.57% increase in SUVmax per 1% increase in high washout; P = .020), and a higher percentage of low plateau kinetics was negatively associated with SUVmax (1.19% decrease in SUVmax per 1% increase in low plateau; P = .003). These relationships were strongest among triple-negative (TN) tumors (4.34% increase in SUVmax per 1% increase in high washout and 2.65% decrease in SUVmax per 1% increase in low plateau; P = .018 and .004, respectively).
CONCLUSION: In invasive breast carcinoma, there is a positive relationship between the percentage of high washout and SUVmax and a negative relationship between the percentage of low plateau and SUVmax. These results are stronger in TN tumors. SUPPLEMENTAL MATERIAL: http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.13130058/-/DC1. RSNA, 2013

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23878283      PMCID: PMC3807081          DOI: 10.1148/radiol.13130058

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  21 in total

Review 1.  Triple-negative breast cancer: present challenges and new perspectives.

Authors:  Franca Podo; Lutgarde M C Buydens; Hadassa Degani; Riet Hilhorst; Edda Klipp; Ingrid S Gribbestad; Sabine Van Huffel; Hanneke W M van Laarhoven; Jan Luts; Daniel Monleon; Geert J Postma; Nicole Schneiderhan-Marra; Filippo Santoro; Hans Wouters; Hege G Russnes; Therese Sørlie; Elda Tagliabue; Anne-Lise Børresen-Dale
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

2.  Dynamic contrast-enhanced MRI of primary rectal cancer: quantitative correlation with positron emission tomography/computed tomography.

Authors:  Jing Gu; Pek-Lan Khong; Silun Wang; Queenie Chan; Ed X Wu; Wailun Law; Rico Kingyin Liu; Jingbo Zhang
Journal:  J Magn Reson Imaging       Date:  2011-02       Impact factor: 4.813

Review 3.  Triple-negative breast cancer.

Authors:  William D Foulkes; Ian E Smith; Jorge S Reis-Filho
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

4.  Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer.

Authors:  David Groheux; Sylvie Giacchetti; Jean-Luc Moretti; Raphael Porcher; Marc Espié; Jacqueline Lehmann-Che; Anne de Roquancourt; Anne-Sophie Hamy; Caroline Cuvier; Laetitia Vercellino; Elif Hindié
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-06       Impact factor: 9.236

5.  Pathophysiologic basis of contrast enhancement in breast tumors.

Authors:  M V Knopp; E Weiss; H P Sinn; J Mattern; H Junkermann; J Radeleff; A Magener; G Brix; S Delorme; I Zuna; G van Kaick
Journal:  J Magn Reson Imaging       Date:  1999-09       Impact factor: 4.813

6.  Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor Histopathology and Angiogenesis in Breast Carcinoma.

Authors:  Laura Esserman; Nola Hylton; Tracy George; Noel Weidner
Journal:  Breast J       Date:  1999-01       Impact factor: 2.431

7.  Partial-volume correction in PET: validation of an iterative postreconstruction method with phantom and patient data.

Authors:  Boon-Keng Teo; Youngho Seo; Stephen L Bacharach; Jorge A Carrasquillo; Steven K Libutti; Himanshu Shukla; Bruce H Hasegawa; Randall A Hawkins; Benjamin L Franc
Journal:  J Nucl Med       Date:  2007-05       Impact factor: 10.057

8.  The relationship between vascular and metabolic characteristics of primary breast tumours.

Authors:  Scott I K Semple; Fiona J Gilbert; Thomas W Redpath; Roger T Staff; Trevor S Ahearn; Andrew E Welch; Steven D Heys; Andrew W Hutcheon; Elizabeth H Smyth; Shailesh Chaturvedi
Journal:  Eur Radiol       Date:  2004-08-14       Impact factor: 5.315

9.  Triple-negative breast cancer: correlation between imaging and pathological findings.

Authors:  Eun Sook Ko; Byung Hee Lee; Hyun-A Kim; Woo-Chul Noh; Min Suk Kim; Sang-Ah Lee
Journal:  Eur Radiol       Date:  2009-11-07       Impact factor: 5.315

10.  Triple-negative breast cancer: correlation between MR imaging and pathologic findings.

Authors:  Takayoshi Uematsu; Masako Kasami; Sachiko Yuen
Journal:  Radiology       Date:  2009-03       Impact factor: 11.105

View more
  11 in total

1.  Characterizing and eliminating errors in enhancement and subtraction artifacts in dynamic contrast-enhanced breast MRI: Chemical shift artifact of the third kind.

Authors:  Jamal J Derakhshan; Elizabeth S McDonald; Evan S Siegelman; Mitchell D Schnall; Felix W Wehrli
Journal:  Magn Reson Med       Date:  2017-08-24       Impact factor: 4.668

2.  Metabolic Tumor Burden Assessed by Dual Time Point [18F]FDG PET/CT in Locally Advanced Breast Cancer: Relation with Tumor Biology.

Authors:  Ana María Garcia-Vicente; Julián Pérez-Beteta; Víctor Manuel Pérez-García; David Molina; German Andrés Jiménez-Londoño; Angel Soriano-Castrejón; Alicia Martínez-González
Journal:  Mol Imaging Biol       Date:  2017-08       Impact factor: 3.488

3.  Dedicated Breast Positron Emission Tomography for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Breast Cancer.

Authors:  Ella F Jones; Kimberly M Ray; Wen Li; Youngho Seo; Benjamin L Franc; Amy J Chien; Laura J Esserman; Miguel H Pampaloni; Bonnie N Joe; Nola M Hylton
Journal:  Clin Breast Cancer       Date:  2016-12-29       Impact factor: 3.225

4.  Kinetic volume analysis on dynamic contrast-enhanced MRI of triple-negative breast cancer: associations with survival outcomes.

Authors:  Yoko Hayashi; Hiroko Satake; Satoko Ishigaki; Rintaro Ito; Mariko Kawamura; Hisashi Kawai; Shingo Iwano; Shinji Naganawa
Journal:  Br J Radiol       Date:  2019-12-16       Impact factor: 3.039

5.  Mask-Guided Convolutional Neural Network for Breast Tumor Prognostic Outcome Prediction on 3D DCE-MR Images.

Authors:  Gengbo Liu; Debasis Mitra; Ella F Jones; Benjamin L Franc; Spencer C Behr; Alex Nguyen; Marjan S Bolouri; Dorota J Wisner; Bonnie N Joe; Laura J Esserman; Nola M Hylton; Youngho Seo
Journal:  J Digit Imaging       Date:  2021-04-22       Impact factor: 4.903

6.  Associations between the standardized uptake value of (18)F-FDG PET/CT and the prognostic factors of invasive lobular carcinoma: in comparison with invasive ductal carcinoma.

Authors:  Na Young Jung; Sung Hun Kim; Bo Bae Choi; Sung Hoon Kim; Mi Sook Sung
Journal:  World J Surg Oncol       Date:  2015-03-15       Impact factor: 2.754

7.  Molecular imaging: from bench to clinic.

Authors:  Yì-Xiáng J Wáng; Yongdoo Choi; Zhiyi Chen; Sophie Laurent; Summer L Gibbs
Journal:  Biomed Res Int       Date:  2014-12-29       Impact factor: 3.411

8.  Semi-quantitative parameter analysis of DCE-MRI revisited: monte-carlo simulation, clinical comparisons, and clinical validation of measurement errors in patients with type 2 neurofibromatosis.

Authors:  Alan Jackson; Ka-Loh Li; Xiaoping Zhu
Journal:  PLoS One       Date:  2014-03-04       Impact factor: 3.240

9.  Relationship between tumor heterogeneity measured on FDG-PET/CT and pathological prognostic factors in invasive breast cancer.

Authors:  Michael Soussan; Fanny Orlhac; Marouane Boubaya; Laurent Zelek; Marianne Ziol; Véronique Eder; Irène Buvat
Journal:  PLoS One       Date:  2014-04-10       Impact factor: 3.240

10.  Textural features and SUV-based variables assessed by dual time point 18F-FDG PET/CT in locally advanced breast cancer.

Authors:  Ana María Garcia-Vicente; David Molina; Julián Pérez-Beteta; Mariano Amo-Salas; Alicia Martínez-González; Gloria Bueno; María Jesús Tello-Galán; Ángel Soriano-Castrejón
Journal:  Ann Nucl Med       Date:  2017-09-08       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.